BRPI0914782A2 - peptídeos de epítopos de cdca1 e vacinas contendo os mesmos - Google Patents

peptídeos de epítopos de cdca1 e vacinas contendo os mesmos

Info

Publication number
BRPI0914782A2
BRPI0914782A2 BRPI0914782A BRPI0914782A BRPI0914782A2 BR PI0914782 A2 BRPI0914782 A2 BR PI0914782A2 BR PI0914782 A BRPI0914782 A BR PI0914782A BR PI0914782 A BRPI0914782 A BR PI0914782A BR PI0914782 A2 BRPI0914782 A2 BR PI0914782A2
Authority
BR
Brazil
Prior art keywords
same
epitope peptides
vaccines containing
cdca1
cdca1 epitope
Prior art date
Application number
BRPI0914782A
Other languages
English (en)
Inventor
Ryuji Ohsawa
Sachiko Yoshimura
Takuya Tsunoda
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI0914782A2 publication Critical patent/BRPI0914782A2/pt
Publication of BRPI0914782B1 publication Critical patent/BRPI0914782B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI0914782-9A 2008-06-19 2009-06-18 Métodos in vitro para indução de uma célula apresentadora de antígeno e linfócito t citotóxico, agente de indução, agente farmacêutico, vacina e uso BRPI0914782B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US7406208P 2008-06-19 2008-06-19
US61/074,062 2008-06-19
US19759908P 2008-10-28 2008-10-28
US61/197,599 2008-10-28
PCT/JP2009/002771 WO2009153992A1 (en) 2008-06-19 2009-06-18 Cdca1 epitope peptides and vaccines containing the same

Publications (2)

Publication Number Publication Date
BRPI0914782A2 true BRPI0914782A2 (pt) 2016-07-26
BRPI0914782B1 BRPI0914782B1 (pt) 2021-08-31

Family

ID=41433910

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914782-9A BRPI0914782B1 (pt) 2008-06-19 2009-06-18 Métodos in vitro para indução de uma célula apresentadora de antígeno e linfócito t citotóxico, agente de indução, agente farmacêutico, vacina e uso

Country Status (16)

Country Link
US (2) US9387238B2 (pt)
EP (1) EP2303912B1 (pt)
JP (1) JP5640262B2 (pt)
KR (2) KR20160119264A (pt)
CN (1) CN102119171B (pt)
AU (1) AU2009261382B2 (pt)
BR (1) BRPI0914782B1 (pt)
CA (1) CA2728268C (pt)
DK (1) DK2303912T3 (pt)
ES (1) ES2658842T3 (pt)
IL (1) IL209967A (pt)
MX (1) MX2010014044A (pt)
RU (1) RU2502740C2 (pt)
SG (1) SG191680A1 (pt)
TW (1) TWI526219B (pt)
WO (1) WO2009153992A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101273144B (zh) 2005-07-27 2011-12-28 肿瘤疗法科学股份有限公司 诊断食道癌的方法
PT2186889E (pt) 2007-08-20 2015-06-17 Oncotherapy Science Inc Péptido cdca1 e agente farmacêutico que o compreende
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
US10208086B2 (en) * 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
US20150359864A1 (en) 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
US9687538B2 (en) * 2012-07-10 2017-06-27 Oncotherapy Science, Inc. CDCA1 epitope peptides for Th1 cells and vaccines containing the same
HRP20211852T1 (hr) 2013-08-05 2022-03-18 Immatics Biotechnologies Gmbh Nova imunoterapija protiv nekoliko tumora, poput raka pluća, uključujući nsclc
TWI777194B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一）
CN113321704B (zh) 2014-08-04 2026-05-12 肿瘤疗法科学股份有限公司 Cdca1衍生的肽和含有它们的疫苗
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
TW202023581A (zh) * 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225553A1 (en) 1995-08-03 1997-02-20 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
JP2002516572A (ja) 1997-05-23 2002-06-04 バイオジェン，インコーポレイテッド 組織の再生の調節
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
WO1999067288A1 (en) 1998-06-25 1999-12-29 Sumitomo Pharmaceuticals Company, Limited Tumor antigen peptides originating in cyclophilin b
US7157091B1 (en) 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20020172952A1 (en) 1999-06-30 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
JP2004500029A (ja) 1999-06-30 2004-01-08 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
US20030170255A1 (en) 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001022920A2 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
EP1343886A2 (en) 2000-07-11 2003-09-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
WO2003025010A2 (en) 2001-09-17 2003-03-27 Eirx Therapeutics Limited Human delta-n p73 molecules and uses thereof
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
WO2003105891A2 (en) 2002-06-12 2003-12-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
AU2003260965A1 (en) 2002-09-30 2004-04-23 Japan As Represented By The President Of The University Of Tokyo Method for diagnosing testicular seminomas
JP2006517094A (ja) * 2002-10-22 2006-07-20 ヌベロ， インコーポレイテッド 新規核酸およびポリペプチド
EP1572736A2 (en) 2002-12-10 2005-09-14 Endocube SAS Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
JP4579246B2 (ja) 2003-09-24 2010-11-10 オンコセラピー・サイエンス株式会社 乳癌を診断する方法
TW200533376A (en) 2004-03-24 2005-10-16 Oncotherapy Science Inc Compositions and methods for treating lung cancer
JP5109131B2 (ja) 2005-02-10 2012-12-26 オンコセラピー・サイエンス株式会社 膀胱癌を診断する方法
CN101273144B (zh) 2005-07-27 2011-12-28 肿瘤疗法科学股份有限公司 诊断食道癌的方法
EP2295570A1 (en) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
EP1915622A2 (en) 2005-07-29 2008-04-30 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
US7776341B2 (en) 2006-08-10 2010-08-17 Colorado State University Research Foundation Biomarkers of tuberculosis that distinguish disease categories: use as serodiagnostic antigens
US8455444B2 (en) 2007-08-20 2013-06-04 Oncotherapy Science, Inc. CDH3 peptide and medicinal agent comprising the same
PT2186889E (pt) 2007-08-20 2015-06-17 Oncotherapy Science Inc Péptido cdca1 e agente farmacêutico que o compreende
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
WO2011030329A1 (en) 2009-09-10 2011-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
US9687538B2 (en) * 2012-07-10 2017-06-27 Oncotherapy Science, Inc. CDCA1 epitope peptides for Th1 cells and vaccines containing the same

Also Published As

Publication number Publication date
JP5640262B2 (ja) 2014-12-17
US20160272692A1 (en) 2016-09-22
JP2011524737A (ja) 2011-09-08
AU2009261382B2 (en) 2013-08-15
EP2303912A1 (en) 2011-04-06
DK2303912T3 (en) 2018-03-12
IL209967A0 (en) 2011-02-28
SG191680A1 (en) 2013-07-31
KR20160119264A (ko) 2016-10-12
RU2502740C2 (ru) 2013-12-27
KR20110031314A (ko) 2011-03-25
CA2728268A1 (en) 2009-12-23
TW201000120A (en) 2010-01-01
TWI526219B (zh) 2016-03-21
WO2009153992A1 (en) 2009-12-23
BRPI0914782B1 (pt) 2021-08-31
CA2728268C (en) 2017-11-07
CN102119171A (zh) 2011-07-06
US9387238B2 (en) 2016-07-12
KR101705011B1 (ko) 2017-02-23
RU2011101709A (ru) 2012-07-27
ES2658842T3 (es) 2018-03-12
EP2303912A4 (en) 2012-08-29
IL209967A (en) 2015-09-24
MX2010014044A (es) 2011-03-03
US10711047B2 (en) 2020-07-14
CN102119171B (zh) 2014-08-06
AU2009261382A1 (en) 2009-12-23
EP2303912B1 (en) 2018-01-03
US20110189214A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
BRPI1008887A2 (pt) peptídeos de foxm1 e vacinas contendo os mesmo
IL211131A0 (en) Inhbb epitope and vaccines containing the same
PL2465864T3 (pl) Szczepionki z peptydem pochodzącym z Eph4
EP2303912A4 (en) CDCA1-EPITOP-PEPTIDES AND VACCINES CONTAINING THEM
EP2318438A4 (en) ANTI-P2X7 PEPTIDES AND EPITOPES
BRPI0811021A2 (pt) Peptídeos e vacinas de tem8 compreendendo os mesmos
BRPI0917391A2 (pt) peptídeo de epítodo de hig2 e urlc10 e vacinas contendo o mesmo
CR10571A (es) Vacuna virica recombinante
IL209869A0 (en) Iqgap3 epitope peptides and vaccines containing the same
IL232461A0 (en) Melk epitope peptides and vaccines containing the same
IL229926A (en) Neil3 peptides and vaccines including the same
IL209870A0 (en) Mybl2 epitope peptides and vaccines containing the same
BRPI0919766A2 (pt) peptídeo de epítopo de rab6kifl/kif20a e vacinas contendo o mesmo
BRPI1012312A2 (pt) peptídeos vangl1 e vacinas incluindo os mesmos
BRPI1010666A2 (pt) peptídeos de cdc45l e vacinas incluindo dos mesmos
BRPI1013938A2 (pt) "peptídeos ttk e vacinas incluindo os mesmos"
BR112013013158A2 (pt) peptídeos de tomm34 e vacinas incluindo os mesmos
BRPI0923402A2 (pt) Peptídeos c10rf59 e vacinas incluindo os mesmos.
BRPI1013384A2 (pt) peptídeos c6orf167 e vacinas incluindo os mesmos
BRPI0922844A2 (pt) peptídeos de epítopo de wdrpuh e vacinas contendo os mesmos
ZA201207342B (en) Ect2 peptides and vaccines including the same
TH0901004695A (th) Rab6kifl/kif20a อิพิโทป เปปไทด์ และ วัคซีนที่ ประกอบด้วยสิ่งเดียวกันนั้น
HK1162528A (en) Wdrpuh epitope peptides and vaccines containing the same
HK1176365A (en) Modified melk peptides and vaccines containing the same
HK1155755A (en) Iqgap3 epitope peptides and vaccines containing the same

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/06/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.